Our results show that CD83 expression in glioma leads to expression profiles related to CTL-mediated antitumor responses and highlight novel mechanisms by which tumor cells could partake in priming of T cell–mediated immunity in glioma. This evidence concerns the gene CD83 and neoplasm.